<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Theophylline use in asthma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Theophylline use in asthma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Theophylline use in asthma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leslie Hendeles, PharmD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Miles Weinberger, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne E Dixon, BM, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> was first identified as having potential for asthma as a bronchodilator in 1921 and 1922 [<a href="#rid1">1</a>], but general use as a bronchodilator was not seen until the 1930s. The combination of theophylline and <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> was described in a 1940 publication [<a href="#rid2">2</a>]. Such preparations, often with a mild sedative added, dominated the market for oral theophylline products until 1975 when the addition of ephedrine was demonstrated to add adverse effects without additive clinical benefit [<a href="#rid3">3</a>]. Theophylline was demonstrated to be the active ingredient in those combinations and a dose-response effect from theophylline was apparent.</p><p>The indications for <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> in the treatment of asthma and recommendations for its safe use will be discussed here. Overviews of the treatment of acute and chronic asthma are provided elsewhere. (See  <a class="medical medical_review" href="/z/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.) </p><p class="headingAnchor" id="H2596351815"><span class="h1">BACKGROUND INFORMATION</span></p><p class="headingAnchor" id="H1273832274"><span class="h2">Theophylline salts</span><span class="headingEndMark"> — </span>Several so-called "salts" of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> had been developed as attempts to increase water solubility (8 mg/mL at 25ºC) and improve absorption. While salts of theophylline may be formed with a base at high pH, theophylline is only slightly ionized at physiological pH (pK<sub>a</sub> = 8.8). Therefore, these so-called salts are merely mixtures of theophylline and base, and they have no effect on the pharmacologic activity of theophylline. </p><p>Since absorption of methylxanthines relates more to their lipophilic characteristics than to their water solubility, there is no rationale for older formulations containing ethylenediamine, calcium salicylate, sodium glycinate, choline, or other bases. Even with <a class="drug drug_general" data-topicid="8620" href="/z/d/drug information/8620.html" rel="external">aminophylline</a> injection still commonly used, the ethylenediamine only serves to increase pH sufficiently to dissolve <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> at the packaged concentration. </p><p>All dosage and labeling of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> formulations should therefore be in terms of the anhydrous theophylline content. For example, <a class="drug drug_general" data-topicid="8620" href="/z/d/drug information/8620.html" rel="external">aminophylline</a> injection USP, 25 mg/mL, is more appropriately labeled "theophylline injection, 20 mg/mL." Intravenous theophylline solution in aqueous solution with 5 percent dextrose without ethylenediamine is available in various concentrations up to 4 mg/mL.</p><p class="headingAnchor" id="H2"><span class="h2">Therapeutic actions</span><span class="headingEndMark"> — </span>Though traditionally classified as a bronchodilator, the ability of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> to control chronic asthma appears disproportionately greater than is explainable by its modest degree of bronchodilator activity alone [<a href="#rid4">4-10</a>]. Theophylline has anti-inflammatory, immunomodulatory, and bronchoprotective effects that potentially contribute to its efficacy as a prophylactic anti-asthma drug [<a href="#rid11">11-16</a>] and for chronic obstructive pulmonary disease (COPD). (See  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Theophylline, monitored by drug levels'</a>.)</p><p>The molecular mechanism of bronchodilatation by <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> is inhibition of phosphodiesterase (PDE)3, but the anti-inflammatory effect may be due to inhibition of PDE4 and activation of histone deacetylases, which are reduced in severe asthma and COPD [<a href="#rid17">17</a>]. Activation of histone deacetylase-2 leads to switching off of activated inflammatory genes, which in turn may contribute to reversal of glucocorticoid resistance by theophylline.</p><p><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> down-regulates inflammatory and immune cell function in vitro and in vivo in animals with airway inflammation [<a href="#rid18">18-20</a>]. In patients with allergic asthma, it attenuates the late phase increase in airway obstruction and airway responsiveness to histamine, decreases allergen-induced migration of activated eosinophils into the bronchial mucosa, and decreases the sputum eosinophil count [<a href="#rid11">11,12,18</a>]. Moreover, withdrawal of theophylline from patients with severe chronic asthma receiving high-doses of inhaled glucocorticoid therapy results in increased symptoms of asthma accompanied by an increase in the number of activated cytotoxic T-lymphocytes in the bronchial mucosa and an increase in helper T-lymphocytes in the airway epithelium [<a href="#rid10">10</a>]. The reduction in nocturnal worsening of lung function when theophylline is used is associated with both a decrease in the percentage of neutrophils and a decrease in stimulated leukotriene B4 from macrophages in early morning bronchoalveolar lavage fluid [<a href="#rid19">19</a>]. An in depth review of in vitro and in vivo studies demonstrating the immunomodulatory, anti-inflammatory, and glucocorticoid-sparing effects of theophylline has been published [<a href="#rid20">20</a>].</p><p>Although several molecular mechanisms have been proposed to explain the actions of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a>, the non-specific inhibition of phosphodiesterase that occurs at clinically relevant drug concentrations appears to be the most important. Theophylline increases the intracellular concentration of cyclic nucleotides in airway smooth muscle and inflammatory cells by inhibiting phosphodiesterase-mediated hydrolysis. However, inhibition of specific isozymes may also be important; inhibition of phosphodiesterase type III and type IV relaxes smooth muscles in pulmonary arteries and in airways [<a href="#rid21">21</a>], while anti-inflammatory and/or immunomodulatory actions probably result from inhibition of the type IV isozymes [<a href="#rid22">22</a>]. This information has stimulated interest in investigating more specific inhibitors of phosphodiesterase type IV for asthma therapy [<a href="#rid23">23,24</a>]. Theophylline also increases histone deacetylase-2 activity, which may increase glucocorticoid responsiveness in patients with glucocorticoid-resistant severe asthma and in patients with asthma who are cigarette smokers [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Clinical circumstances for which <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> may be considered in the treatment of asthma include the following (see  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Additive maintenance therapy in a patient whose asthma is not adequately controlled with conventional doses of inhaled therapies such as inhaled glucocorticoids, long-acting beta-agonists, and long-acting muscarinic antagonists [<a href="#rid26">26</a>]. Biologic therapies are generally preferred for this group of patients. However, not all patients qualify for biologic therapies and these therapies are also not universally available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary maintenance therapy when the administration of an inhaled glucocorticoid is difficult or cumbersome (eg, toddlers and preschool-age children) and <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> is not effective, although <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> is not a preferred agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary maintenance therapy in a patient who is more likely to adhere to an oral than an inhaled regimen and <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> is not sufficiently effective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possibly, additive acute therapy in the intensive care unit for patients failing to respond to vigorous use of inhaled beta2-selective agonists in combination with <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> and/or intravenous magnesium and systemically administered glucocorticoids, although evidence for benefit in this situation is lacking. (See <a class="local">'Additive or maintenance acute therapy for hospitalized patients'</a> below.)</p><p></p><p class="headingAnchor" id="H3619314459"><span class="h1">EVIDENCE OF EFFICACY, BY INDICATION</span></p><p class="headingAnchor" id="H4"><span class="h2">Add-on to maintenance inhaled glucocorticoids</span><span class="headingEndMark"> — </span>Moderate and even high doses of inhaled glucocorticoids (GC) may provide inadequate control of asthma in some patients despite optimal compliance and technique [<a href="#rid5">5,8,10,27-30</a>] and may be accompanied by systemic side effects. (See  <a class="medical medical_review" href="/z/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids"</a>.)</p><p>Randomized trials confirm that the addition of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> results in better pulmonary function and symptom control than an increased dose of inhaled GC  (<a class="graphic graphic_figure graphicRef65496" href="/z/d/graphic/65496.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef75636" href="/z/d/graphic/75636.html" rel="external">figure 2</a>) [<a href="#rid5">5,8,10,29</a>]. (See  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>For example, one study randomly assigned 62 patients to treatment with 800 mcg/day of inhaled <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> or the combination of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> and 400 mcg/day of inhaled budesonide [<a href="#rid29">29</a>]. The doses of theophylline administered were 250 mg or 375 mg, twice daily, for patients weighing &lt;80 kg or ≥80 kg, respectively. The median serum concentration was 8.7 mcg/mL, below the commonly-employed therapeutic range (10 to 20 mcg/mL). Combination therapy resulted in significantly greater forced expiratory flow in the first second (FEV<sub>1</sub>) and forced vital capacity (FVC), while there were no differences between the groups in terms of beta-agonist use or peak expiratory flow variability. Adverse events were similar in both treatment groups. (See <a class="local">'Target peak serum concentration'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, withdrawal of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> in a double blind fashion from 27 patients with severe chronic asthma resulted in a significant increase in asthma symptoms, particularly at night, and a fall in spirometry and morning peak flow performance [<a href="#rid10">10</a>].</p><p></p><p>The ability of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> to help control chronic asthma in these and other studies has been disproportionate to its relatively mild bronchodilator activity. For this reason, additional mechanisms of theophylline activity have been postulated [<a href="#rid31">31</a>], including anti-inflammatory and immunomodulatory effects [<a href="#rid10">10-12,20</a>]. (See <a class="local">'Therapeutic actions'</a> above.)</p><p class="headingAnchor" id="H5"><span class="h3">Comparison with other add-on therapies</span><span class="headingEndMark"> — </span>There are few studies directly comparing the addition of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> to the addition of other controller therapies (antileukotriene agents, long-acting beta-agonists [LABAs]) in patients receiving inhaled GC therapy, and no studies comparing theophylline with biologic agents. Anti-leukotriene agents and theophylline have the "real-world" advantage of being orally administered rather than inhaled. Many patients find an oral agent simpler to administer than an additional metered dose inhaler, and adherence is greater, on average, with an oral medication [<a href="#rid32">32</a>].</p><p>Only inhaled LABAs, such as <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> and <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, have been demonstrated to be superior to <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> in head-to-head studies for additive effect [<a href="#rid33">33,34</a>], although not all patients benefit from LABAs. Mixed results have been noted in comparisons with leukotriene receptor antagonists, such as <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> [<a href="#rid35">35-39</a>]. Inhaled <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> will generally have much less effect [<a href="#rid4">4,40,41</a>] and is only available as a nebulizer solution in the United States. (See <a class="local">'Add-on to maintenance inhaled glucocorticoids'</a> above and  <a class="medical medical_review" href="/z/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Primary maintenance therapy when oral agents are preferred</span><span class="headingEndMark"> — </span>One potential advantage of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> is increased likelihood of patient adherence to regular oral therapy compared with maintenance therapy with inhaled GC. Several reports indicate poor adherence to regimens of inhaled maintenance medications, while theophylline appears to cause less difficulty with adherence [<a href="#rid32">32,42</a>].</p><p>For most patients with asthma, particularly those with poor adherence, current guidelines recommend anti-inflammatory reliever (AIR) strategies, which deliver inhaled glucocorticoids as needed for worsening symptoms [<a href="#rid43">43,44</a>]. <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> and AIR have not been directly compared. However, cost, unavailability, and lack of regulatory approval for some forms of AIR may prevent the routine use of this therapy in many patients, including in children where there is more limited data.</p><p class="headingAnchor" id="H7"><span class="h2">Additive or maintenance acute therapy for hospitalized patients</span><span class="headingEndMark"> — </span>In general, limited benefit is derived by adding intravenous <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a>, in the form of theophylline or <a class="drug drug_general" data-topicid="8620" href="/z/d/drug information/8620.html" rel="external">aminophylline</a> (theophylline with ethylenediamine in an 80-85/15-20 percent ratio), to intensely administered inhaled beta agonists and systemic glucocorticoids for patients hospitalized with an acute asthma exacerbation [<a href="#rid45">45,46</a>]. More detailed discussions of the use of theophylline in the management of acute exacerbations of asthma in adults and children are provided separately. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Ineffective therapies'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">SAFE USE OF THEOPHYLLINE</span></p><p class="headingAnchor" id="H1209136776"><span class="h2">General approach</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> has a narrow therapeutic index and wide interpatient variability in clearance. Consequently, dosing must be individually titrated to appropriate steady-state serum concentrations in order to achieve maximal benefit and safety. This requires skill and knowledge on the part of the clinician and an ability of patients or caregivers to follow instructions properly [<a href="#rid47">47,48</a>]. Many trials of "low-dose" theophylline either demonstrated likely therapeutic peak theophylline levels, which should be monitored, or were not effective.</p><p>Failure to adequately monitor <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> use can lead to potentially fatal drug intoxication. Theophylline should generally be avoided or used with great caution in patients predisposed to toxic effects of theophylline, such as those with cardiac tachyarrhythmias or seizure disorders. (See  <a class="medical medical_review" href="/z/d/html/6501.html" rel="external">"Theophylline poisoning"</a>.)</p><p><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> is generally well tolerated and there is little risk of serious toxicity when the drug is administered properly [<a href="#rid47">47</a>]. As an example, one epidemiologic investigation of 36,000 ambulatory patients who received 225,000 prescriptions for theophylline over a nine year period found that the risk of hospital admission due to complications of chronic theophylline use was less than 1 per 1000 patient-years of exposure [<a href="#rid49">49</a>].</p><p>Factors that must be considered to maximize the safety of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> include proper target serum concentration, appropriate dosage titration, the presence of conditions or factors that affect theophylline metabolism, and proper product and dosing interval selection.</p><p class="headingAnchor" id="H10"><span class="h2">Target peak serum concentration</span><span class="headingEndMark"> — </span>The efficacy and toxicity of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> are closely related to the <strong>peak </strong>serum concentration  (<a class="graphic graphic_table graphicRef75856" href="/z/d/graphic/75856.html" rel="external">table 1</a>). In patients receiving theophylline monotherapy, doses providing a <strong>peak</strong> serum concentration of 10 to 20 mg/L (mcg/mL) are best documented to improve symptoms and reduce the need for rescue therapy [<a href="#rid50">50-52</a>]. Targeting a peak of 15 mg/L allows for some dose-to-dose fluctuation and avoids exceeding 20 mg/L and the associated adverse effects [<a href="#rid47">47,53</a>].</p><p>There has been interest in using lower concentrations [<a href="#rid10">10,12,29,54</a>]. However, the results of these studies have been divergent, likely in part due to nonstandardized or absent individual patient-level monitoring. The best studies of low-dose <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> have not been favorable. For example, in one placebo-controlled trial of 489 adults and adolescents &gt;15 years, addition of low-dose theophylline (300 mg/d) to inhaled corticosteroids did not improve asthma control [<a href="#rid36">36</a>]; patients who received theophylline who were not on inhaled glucocorticoids showed improvement in asthma symptoms.</p><p class="headingAnchor" id="H11"><span class="h2">Initiating and titrating oral therapy</span><span class="headingEndMark"> — </span>When beginning <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> for maintenance therapy, the initial dose should be sufficiently low to avoid transient caffeine-like side effects such as insomnia and irritability. In non-smoking adults without risk factors for reduced theophylline clearance, a starting daily dose of 300 mg is appropriate in most cases. A sustained release product should be used from the beginning. For children, an appropriate starting dose is 10 mg per kg of body weight per day to a maximum of 300 mg/day. In patients with obesity, ideal body weight is used in this calculation (<a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">calculator 1</a>).</p><p>The dose is then increased at intervals of three days or more until the average dose requirements for age are approached  (<a class="graphic graphic_table graphicRef53731" href="/z/d/graphic/53731.html" rel="external">table 2</a>). If a particular dose increase produces unacceptable side effects (eg, tremor, tachycardia, vomiting, abdominal pain), the dose should be reduced to that which had been previously tolerated. A single peak serum concentration measurement is then obtained at the highest tolerated dose, and the final dose is adjusted accordingly  (<a class="graphic graphic_table graphicRef53731" href="/z/d/graphic/53731.html" rel="external">table 2</a>). Fewer than 3 percent of children and 10 percent of adults experience intolerance to <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> at peak serum concentrations less than 20 mg/L if a slow titration schedule is used, such as the one listed in the table  (<a class="graphic graphic_table graphicRef53731" href="/z/d/graphic/53731.html" rel="external">table 2</a>) [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/6501.html" rel="external">"Theophylline poisoning"</a>.)</p><p>In patients with risk factors for reduced <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> clearance or in whom the serum concentration cannot be measured in a timely fashion, the maximum daily dose should not exceed 10 mg per kg/day or 400 mg/day, whichever is lower [<a href="#rid55">55</a>].</p><p>Generally only one, and uncommonly two, serum concentration measurements are required to achieve a therapeutic peak concentration [<a href="#rid47">47</a>]. The initial measurement is made at the end of the dose titration schedule  (<a class="graphic graphic_table graphicRef53731" href="/z/d/graphic/53731.html" rel="external">table 2</a>). To properly measure the peak concentration, a blood sample should be obtained at the time of an estimated peak concentration for the formulation used  (<a class="graphic graphic_table graphicRef75856" href="/z/d/graphic/75856.html" rel="external">table 1</a>). In the absence of intercurrent illness associated with sustained fever or drug interactions, serum concentrations can be expected to remain relatively stable, and repeat measurement in 6 to 12 months is generally sufficient [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Factors affecting metabolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> is metabolized predominately in the liver by the enzyme cytochrome P450 1A2, and to a lesser extent by P450 3A3 and P450 2E1 [<a href="#rid56">56</a>]. Genetic factors, concurrent diseases, environmental agents, and other drugs that alter the activity of these isozymes affect the metabolism of theophylline. For example, cystic fibrosis has been found to increase the clearance of theophylline [<a href="#rid57">57,58</a>]. More commonly, when the rate of theophylline metabolism is reduced, the total daily dose must be appropriately decreased to prevent excessive accumulation and toxicity [<a href="#rid59">59</a>].</p><p>The following are risk factors for reduced <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> clearance:</p><p class="bulletIndent1"><span class="glyph">●</span>Age less than 1 year or greater than 60 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent diseases such as acute pulmonary edema, heart failure, cor pulmonale, fever above 38.9ºC (102ºF) for more than 24 hours, hypothyroidism, liver disease, reduced renal function in infants less than three months of age, and sepsis with multiorgan failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent smoking cessation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy, particularly during the third trimester, is associated with an increase in the volume of distribution and elimination half-life for <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> [<a href="#rid56">56</a>]. Clearance of theophylline is therefore decreased in the third trimester but returns to normal postpartum [<a href="#rid60">60</a>]. Decreased binding to albumin during pregnancy results in an increased proportion of free drug in the circulation [62]. Decrease in binding means that more free-drug is available for metabolism. Because of these variables, theophylline serum concentration should be monitored during the last half of pregnancy and postpartum [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/554.html" rel="external">"Management of asthma during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Addition of a drug that inhibits <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> metabolism (eg, azole antifungal agents such as <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, tacrine) or discontinuation of a concurrently administered drug that enhances theophylline metabolism (eg, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>). There are multiple drug interactions. When initiating or altering drug therapy, use of a drug interactions database, such as the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate, is advised. In practice, maintaining a safe and stable dose is most challenging for older patients with multiple comorbidities and complex medication regimens, and theophylline is rarely used in this setting. (See  <a class="medical medical_review" href="/z/d/html/521.html" rel="external">"Diagnosis and management of asthma in older adults"</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Selection of product and dosing interval</span><span class="headingEndMark"> — </span>Slow-release formulations allow a longer dosing interval than rapid release formulations but vary in their rates and completeness of absorption  (<a class="graphic graphic_table graphicRef75856" href="/z/d/graphic/75856.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Food caused a precipitous increase in the rate of absorption and peak concentration with the formulation marketed as Theo-24 [<a href="#rid62">62</a>], whereas taking the formulation identified as Uniphyl on an empty stomach resulted in a marked decrease in absorption [<a href="#rid59">59</a>]. Only products that are completely and consistently absorbed should be selected. US Food and Drug Administration (FDA) AB-rated generic slow-release tablets or capsules for twice daily dosing are the preferred agents.</p><p></p><p>The difference between the peak and trough serum concentrations is a function of the rate of absorption of the product, the dosing interval selected by the clinician, and the rate of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> metabolism by the patient [<a href="#rid63">63</a>]. In patients with rapid metabolism, such as children, even a formulation as slowly absorbed as Uniphyl is likely to result in a large difference between the peak and trough, whereas administration of the Uniphyl formulation once-nightly in patients with slower metabolism, as in many adults, may provide acceptable fluctuations between the peak and trough concentrations [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>After initial titration of the dose, we suggest checking the <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> serum concentration at the estimated peak  (<a class="graphic graphic_table graphicRef75856" href="/z/d/graphic/75856.html" rel="external">table 1</a>), every 12 months, unless a change in concomitant medications or health status (eg, pregnancy, symptoms of toxicity, or child with rapid growth) dictates a shorter interval.</p><p class="headingAnchor" id="H89594425"><span class="h2">Dosing of IV theophylline</span><span class="headingEndMark"> — </span>For patients who are on chronic <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> and unable to take oral medication during an acute exacerbation, the serum level should be assessed and intravenous (IV) theophylline administered at a maintenance infusion rate, adjusted if needed to achieve a peak serum concentration of 10 to 20 mg/L.</p><p>For patients not previously receiving <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a>, a single intravenous loading dose of theophylline, 5 mg/kg, will provide a peak serum theophylline concentration of about 10 to 15 mcg/mL and may be justified for patients with severe acute symptoms that do not respond rapidly to routine measures. There is minimal risk for serious toxicity with such a dose, and a maintenance infusion may then be initiated if obvious clinical improvement results [<a href="#rid64">64</a>]. Choice of a maintenance infusion rate depends on factors such as age, smoking status, and concomitant medical problems that may alter theophylline clearance. Measurement of serum concentrations is performed approximately four hours after initiation of continuous infusion and then every 12 hours until a therapeutic and stable concentration is reached. After this point, there is no reason to repeat the measurement unless factors affecting theophylline pharmacokinetics change. (See <a class="local">'Factors affecting metabolism'</a> above.)</p><p>Additional information about intravenous administration of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> is provided separately. (See  <a class="drug drug_general" href="/z/d/drug information/10281.html" rel="external">"Theophylline: Drug information"</a>.)</p><p class="headingAnchor" id="H3330695260"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112325.html" rel="external">"Society guideline links: Asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> has bronchodilatory, anti-inflammatory, immunomodulating, and bronchoprotective effects. (See <a class="local">'Therapeutic actions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> remains a potentially useful and inexpensive medication as an add-on agent for patients with persistent asthma whose symptoms are not controlled with conventional doses of inhaled controller therapies and as bronchodilator therapy for those who cannot take or are poorly adherent to inhaled medications. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The addition of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> to moderate- to high-dose inhaled glucocorticoids is more effective than increasing the dose of inhaled glucocorticoids. (See <a class="local">'Add-on to maintenance inhaled glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> is less effective than long-acting beta-agonists as add-on therapy and has not been compared with other add-on agents (including biologics). (See <a class="local">'Comparison with other add-on therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> has not been demonstrated to improve acute severe asthma in the intensive care unit.(See <a class="local">'Additive or maintenance acute therapy for hospitalized patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safe use of </strong><strong>theophylline</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General principles</strong> – <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> has a narrow therapeutic index and wide interpatient variability in clearance. Safe use of oral theophylline as a maintenance therapy requires initiating treatment at a low dose, measuring a serum concentration to adjust the dose, and reducing the dose in the presence of physiologic states or medications that impair theophylline metabolism. (See <a class="local">'Safe use of theophylline'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Targeting peak serum concentration</strong> – The efficacy and toxicity of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> are closely related to the <strong>peak</strong> serum concentration  (<a class="graphic graphic_table graphicRef75856" href="/z/d/graphic/75856.html" rel="external">table 1</a>). In patients receiving theophylline monotherapy, doses providing a peak serum concentration of 10 to 20 mg/L (mcg/mL) are best documented to improve symptoms and reduce the need for rescue therapy. (See <a class="local">'Target peak serum concentration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initiating and monitoring therapy</strong> – We use a starting daily dose of 300 mg (10 mg/kg ideal body weight to a maximum of 300 mg in children) in most cases. The dose should be increased at intervals of three days or more up to the average dose requirements for age  (<a class="graphic graphic_table graphicRef53731" href="/z/d/graphic/53731.html" rel="external">table 2</a>). If a particular dose increase produces unacceptable side effects (eg, tremor, tachycardia, vomiting, abdominal pain), the dose should be reduced to that which had been previously tolerated. The dose is adjusted based on serum peak concentration obtained based on the formulation  (<a class="graphic graphic_table graphicRef75856" href="/z/d/graphic/75856.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef53731" href="/z/d/graphic/53731.html" rel="external">table 2</a>). After initial titration of the dose, we check the <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> peak serum concentration every 6 to 12 months unless there is a change in concomitant medications or health status.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Factors affecting metabolism</strong> – Age less than 1 or greater than 60 years, pregnancy, recent smoking cessation, use of interacting pharmacologic agents, or concurrent comorbid disease affecting heart, liver, kidney, or thyroid function can alter <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> metabolism and create the potential for toxicity. (See <a class="local">'Factors affecting metabolism'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selection of product and dosing interval</strong> – The absorption characteristics of specific formulations vary considerably, particularly with regards to the effects of food  (<a class="graphic graphic_table graphicRef75856" href="/z/d/graphic/75856.html" rel="external">table 1</a>). Familiarity with these details is important. (See <a class="local">'Selection of product and dosing interval'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intravenous dosing</strong> – In patients already on <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a>, an infusion rate can be adjusted by serum level. (See <a class="local">'Dosing of IV theophylline'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">May CD. History of the introduction of theophylline into the treatment of asthma. Clin Allergy 1974; 4:211.</a></li><li><a class="nounderline abstract_t">Brown EA. New type of medication to be used in bronchial asthma and other allergic conditions. N Engl J Med 1940; 223:843.</a></li><li><a class="nounderline abstract_t">Weinberger MM, Bronsky EA. Interaction of ephedrine and theophylline. Clin Pharmacol Ther 1975; 17:585.</a></li><li><a class="nounderline abstract_t">Hambleton G, Weinberger M, Taylor J, et al. Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma. A collaborative study. Lancet 1977; 1:381.</a></li><li><a class="nounderline abstract_t">Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med 1981; 304:71.</a></li><li><a class="nounderline abstract_t">Dusdieker L, Green M, Smith GD, et al. Comparison of orally administered metaproterenol and theophylline in the control of chronic asthma. J Pediatr 1982; 101:281.</a></li><li><a class="nounderline abstract_t">Joad JP, Ahrens RC, Lindgren SD, Weinberger MM. Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. J Allergy Clin Immunol 1987; 79:78.</a></li><li><a class="nounderline abstract_t">Brenner M, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 1988; 18:143.</a></li><li><a class="nounderline abstract_t">Rivington RN, Boulet LP, Côté J, et al. Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995; 151:325.</a></li><li><a class="nounderline abstract_t">Kidney J, Dominguez M, Taylor PM, et al. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151:1907.</a></li><li><a class="nounderline abstract_t">Hendeles L, Harman E, Huang D, et al. Theophylline attenuation of airway responses to allergen: comparison with cromolyn metered-dose inhaler. J Allergy Clin Immunol 1995; 95:505.</a></li><li><a class="nounderline abstract_t">Sullivan P, Bekir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343:1006.</a></li><li><a class="nounderline abstract_t">Magnussen H, Reuss G, Jörres R. Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics. Am Rev Respir Dis 1987; 136:1163.</a></li><li><a class="nounderline abstract_t">Koenig JQ, Dumler K, Rebolledo V, et al. Theophylline mitigates the bronchoconstrictor effects of sulfur dioxide in subjects with asthma. J Allergy Clin Immunol 1992; 89:789.</a></li><li><a class="nounderline abstract_t">Fabbri LM, Alessandri MV, De Marzo N, et al. Long-lasting protective effect of slow-release theophylline on asthma induced by ultrasonically nebulized distilled water. Ann Allergy 1986; 56:171.</a></li><li><a class="nounderline abstract_t">Pollock J, Kiechel F, Cooper D, Weinberger M. Relationship of serum theophylline concentration to inhibition of exercise-induced bronchospasm and comparison with cromolyn. Pediatrics 1977; 60:840.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Theophylline. Am J Respir Crit Care Med 2013; 188:901.</a></li><li><a class="nounderline abstract_t">Horiguchi T, Tachikawa S, Kasahara J, et al. Suppression of airway inflammation by theophylline in adult bronchial asthma. Respiration 1999; 66:124.</a></li><li><a class="nounderline abstract_t">Kraft M, Torvik JA, Trudeau JB, et al. Theophylline: potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol 1996; 97:1242.</a></li><li><a class="nounderline abstract_t">Markham A, Faulds D. Theophylline. A review of its potential steroid sparing effects in asthma. Drugs 1998; 56:1081.</a></li><li><a class="nounderline abstract_t">Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995; 8:637.</a></li><li><a class="nounderline abstract_t">Lagente V, Pruniaux MP, Junien JL, Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am J Respir Crit Care Med 1995; 151:1720.</a></li><li><a class="nounderline abstract_t">Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365:167.</a></li><li><a class="nounderline abstract_t">Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157:351.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009; 3:235.</a></li><li><a class="nounderline abstract_t">Weinberger M, Abu-Hasan M. Life-threatening asthma during treatment with salmeterol. N Engl J Med 2006; 355:852.</a></li><li><a class="nounderline abstract_t">Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen &amp; Hanburys Limited UK Study Group. Lancet 1994; 344:219.</a></li><li><a class="nounderline abstract_t">Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481.</a></li><li><a class="nounderline abstract_t">Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337:1412.</a></li><li><a class="nounderline abstract_t">Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 2009; 33:1010.</a></li><li><a class="nounderline abstract_t">Vassallo R, Lipsky JJ. Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc 1998; 73:346.</a></li><li><a class="nounderline abstract_t">Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154:1349.</a></li><li><a class="nounderline abstract_t">Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med 1998; 92:256.</a></li><li><a class="nounderline abstract_t">Paggiaro PL, Giannini D, Di Franco A, Testi R. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. Eur Respir J 1996; 9:1689.</a></li><li><a class="nounderline abstract_t">Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91:49.</a></li><li><a class="nounderline abstract_t">American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175:235.</a></li><li><a class="nounderline abstract_t">Yurdakul AS, Taci N, Eren A, Sipit T. Comparative efficacy of once-daily therapy with inhaled corticosteroid, leukotriene antagonist or sustained-release theophylline in patients with mild persistent asthma. Respir Med 2003; 97:1313.</a></li><li><a class="nounderline abstract_t">Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clin Ther 2015; 37:418.</a></li><li><a class="nounderline abstract_t">Kondo N, Katsunuma T, Odajima Y, Morikawa A. A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children. Allergol Int 2006; 55:287.</a></li><li><a class="nounderline abstract_t">Newth CJ, Newth CV, Turner JA. Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. Aust N Z J Med 1982; 12:232.</a></li><li><a class="nounderline abstract_t">Furukawa CT, Shapiro GG, Bierman CW, et al. A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma. Pediatrics 1984; 74:453.</a></li><li><a class="nounderline abstract_t">Sherman J, Hutson A, Baumstein S, Hendeles L. Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions. J Pediatr 2000; 136:532.</a></li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), Cloutier MM, Baptist AP, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146:1217.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on March 17, 2016.).</li><li><a class="nounderline abstract_t">Mahemuti G, Zhang H, Li J, et al. Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis. Drug Des Devel Ther 2018; 12:99.</a></li><li><a class="nounderline abstract_t">Milavetz G, Vaughan LM, Weinberger MM, Hendeles L. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. J Pediatr 1986; 109:351.</a></li><li><a class="nounderline abstract_t">Asmus MJ, Weinberger MM, Milavetz G, et al. Apparent decrease in population clearance of theophylline: implications for dosage. Clin Pharmacol Ther 1997; 62:483.</a></li><li><a class="nounderline abstract_t">Derby LE, Jick SS, Langlois JC, et al. Hospital admission for xanthine toxicity. Pharmacotherapy 1990; 10:112.</a></li><li><a class="nounderline abstract_t">Weinberger MM, Bronsky EA. Evaluation of oral bronchodilator therapy in asthmatic children. Bronchodilators in asthmatic children. J Pediatr 1974; 84:421.</a></li><li><a class="nounderline abstract_t">Neijens HJ, Duiverman EJ, Graatsma BH, Kerrebijn KF. Clinical and bronchodilating efficacy of controlled-release theophylline as a function of its serum concentrations in preschool children. J Pediatr 1985; 107:811.</a></li><li><a class="nounderline abstract_t">Jenne JW. Reassessing the therapeutic range for theophylline on laboratory report forms: another viewpoint. Pharmacotherapy 1993; 13:595.</a></li><li><a class="nounderline abstract_t">Weinberger M, Hendeles L. Therapeutic effect and dosing strategies for theophylline in the treatment of chronic asthma. J Allergy Clin Immunol 1986; 78:762.</a></li><li><a class="nounderline abstract_t">Ukena D, Harnest U, Sakalauskas R, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997; 10:2754.</a></li><li><a class="nounderline abstract_t">Hendeles L, Jenkins J, Temple R. Revised FDA labeling guideline for theophylline oral dosage forms. Pharmacotherapy 1995; 15:409.</a></li><li><a class="nounderline abstract_t">Frederiksen MC, Ruo TI, Chow MJ, Atkinson AJ Jr. Theophylline pharmacokinetics in pregnancy. Clin Pharmacol Ther 1986; 40:321.</a></li><li><a class="nounderline abstract_t">Isles A, Spino M, Tabachnik E, et al. Theophylline disposition in cystic fibrosis. Am Rev Respir Dis 1983; 127:417.</a></li><li><a class="nounderline abstract_t">Knoppert DC, Spino M, Beck R, et al. Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease. Clin Pharmacol Ther 1988; 44:254.</a></li><li><a class="nounderline abstract_t">Milavetz G, Vaughan LM, Weinberger MM, et al. Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing. J Allergy Clin Immunol 1987; 80:723.</a></li><li><a class="nounderline abstract_t">Gardner MJ, Schatz M, Cousins L, et al. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. Eur J Clin Pharmacol 1987; 32:289.</a></li><li><a class="nounderline abstract_t">Connelly TJ, Ruo TI, Frederiksen MC, Atkinson AJ Jr. Characterization of theophylline binding to serum proteins in pregnant and nonpregnant women. Clin Pharmacol Ther 1990; 47:68.</a></li><li><a class="nounderline abstract_t">Hendeles L, Weinberger M, Milavetz G, et al. Food-induced "dose-dumping" from a once-a-day theophylline product as a cause of theophylline toxicity. Chest 1985; 87:758.</a></li><li><a class="nounderline abstract_t">Weinberger M, Hendeles L, Wong L. Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma. J Pediatr 1981; 99:145.</a></li><li><a class="nounderline abstract_t">Hendeles L, Weinberger M, Bighley L. Disposition of theophylline after a single intravenous infusion of aminophylline. Am Rev Respir Dis 1978; 118:97.</a></li></ol></div><div id="topicVersionRevision">Topic 560 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4601857" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : History of the introduction of theophylline into the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New type of medication to be used in bronchial asthma and other allergic conditions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interaction of ephedrine and theophylline</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/65508" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma. A collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7003383" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The value of maintenance theophylline in steroid-dependent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7047707" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of orally administered metaproterenol and theophylline in the control of chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805550" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3365858" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Need for theophylline in severe steroid-requiring asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842186" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7767539" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7852666" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Theophylline attenuation of airway responses to allergen: comparison with cromolyn metered-dose inhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909049" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Anti-inflammatory effects of low-dose oral theophylline in atopic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3314612" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1560163" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Theophylline mitigates the bronchoconstrictor effects of sulfur dioxide in subjects with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3946851" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-lasting protective effect of slow-release theophylline on asthma induced by ultrasonically nebulized distilled water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/414196" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relationship of serum theophylline concentration to inhibition of exercise-induced bronchospasm and comparison with cromolyn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23672674" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Theophylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202315" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Suppression of airway inflammation by theophylline in adult bronchial asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648019" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Theophylline: potential antiinflammatory effects in nocturnal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9878995" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Theophylline. A review of its potential steroid sparing effects in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7664866" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539326" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15639300" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9476844" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19812111" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Histone deacetylase-2 and airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16929006" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Life-threatening asthma during treatment with salmeterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913155" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen&amp;Hanburys Limited UK Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630590" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9358138" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196814" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9559039" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8002686" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of patients' compliance with prescribed oral and inhaled asthma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9616522" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8866596" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12877449" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16998094" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14682413" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparative efficacy of once-daily therapy with inhaled corticosteroid, leukotriene antagonist or sustained-release theophylline in patients with mild persistent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577543" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075269" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6810863" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6435085" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753254" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753254" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33280709" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33280709" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29391776" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3734974" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390104" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Apparent decrease in population clearance of theophylline: implications for dosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2349136" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hospital admission for xanthine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4590718" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evaluation of oral bronchodilator therapy in asthmatic children. Bronchodilators in asthmatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4056987" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical and bronchodilating efficacy of controlled-release theophylline as a function of its serum concentrations in preschool children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8302683" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reassessing the therapeutic range for theophylline on laboratory report forms: another viewpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3534057" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Therapeutic effect and dosing strategies for theophylline in the treatment of chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9493656" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7479193" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Revised FDA labeling guideline for theophylline oral dosage forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3742937" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Theophylline pharmacokinetics in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6838048" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Theophylline disposition in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3046811" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3680816" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3595701" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Longitudinal effects of pregnancy on the pharmacokinetics of theophylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2295221" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Characterization of theophylline binding to serum proteins in pregnant and nonpregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3996063" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Food-induced "dose-dumping" from a once-a-day theophylline product as a cause of theophylline toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7252652" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/677562" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Disposition of theophylline after a single intravenous infusion of aminophylline.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
